PCVXVAXCYTE, INC.Mid cap · $8.23B · FY ending 2025-12-31
$57.03-2.03% · 2026-07-13 · EOD
41/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality—
margins & F-ScoreValue10
valuation vs its own rangeMomentum71
golden · price above 200-daySmart Money42
buying · 1 funds · 0P/12S insidersBullish stackGolden crossAbove 200-day
vs S&P 500+17.2%
6-mo excess Trailing performance1M +25.6%
3M -6.3%
6M +25.8%
YTD +22.8%
1Y +57.4%
Not enough profitable-period data to value PCVX on earnings.
ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of ~21%. Annual figures from SEC XBRL.
Net buying0P / 12S insiders · 1 funds hold · 2 Congress buys
Recent insidersWassil Jim · CHIEF OPERATING OFFICERSELL$126,736
GUGGENHIME ANDREW · PRESIDENT AND CFOSELL$572,837
PICKERING GRANT · CHIEF EXECUTIVE OFFICERSELL$1.3M
GUGGENHIME ANDREW · PRESIDENT AND CFOSELL$530,000
Fund holders (13F)Baupost Group (Seth Klarman)$46,4880.9% of book
Bhealth · 77/100
Self-fundingSelf-funding — generates cash
- ●Active dilution shelf An effective S-3 shelf with 3 prospectus filing(s) in 12 months — shares may be getting sold into the market.
- ●One-sided insider selling 12 insider sales and no open-market buys in the recent window.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.